Treatmenta | Proliferationb | ||
---|---|---|---|
HeLa Cells | MCF-7 Cells | ||
A) SC siRNA | 100 ± 1.1 | 100 ± 1.0 | |
B) TS siRNA | 95 ± 1.3* | 94 ± 2.2* | |
C) Bcl-2 siRNA 1 | 77 ± 2.8* | 76 ± 1.6* | |
D) Bcl-2 siRNA 2 | 85 ± 2.5* | 91 ± 2.2* | |
E) TS siRNA + Bcl-2 siRNA 1 | 68 ± 0.8* | 66 ± 1.2 | |
F) TS siRNA + Bcl-2 siRNA 2 | 71 ± 1.8* | 78 ± 1.7 | |
G) SC siRNA | 98.5 ± 6.0 | 95.3 ± 1.2* | |
H) No siRNA (control) | 100 ± 2.5 | 100 ± 1.6 |
↵* Different from untreated cells (p ≤ 0.05, Student's t test).
↵ a Total siRNA concentration was 100 nM for all treatments (A—G).
↵ b For treatments A to F, “proliferation” was the number of cells 5 days after treatment with siRNAs targeting TS and/or Bcl-2 (percentage of the number of cells treated with SC siRNA). For treatment G, proliferation was the number of cells 5 days after treatment with SC siRNA is shown (percentage of the number of control cells, untreated with siRNA). Numbers are means ± S.E. (two independent experiments, n = 3 for each experiment).